Alex de la Fuente

Statistics

Publications

Citations

230

H-Index

Active since

2001

Affiliations

Institute for Research in Biomedicine(Current)

Universitat de Barcelona

Instituto de Investigaciones Químicas

Universidad de Sevilla

Alex de la Fuente is an author at Institute for Research in Biomedicine specializing in medicinal chemistry, stereoselective synthesis, and pharmacology.

Publications per year

2001–2016

Publications

EPI-001, A Compound Active against Castration-Resistant Prostate Cancer, Targets Transactivation Unit 5 of the Androgen Receptor

Eva De Mol, R. Bryn Fenwick, Christopher T. W. Phang et al. · ACS Chemical Biology · 2016 · 156 citations · Full text

Medicine, Medicinal Chemistry, Oncology +17

Efficient stereoselective synthesis of 2-acetamido-1,2-dideoxyallonojirimycin (DAJNAc) and sp2-iminosugar conjugates: Novel hexosaminidase inhibitors with discrimination capabilities between the mature and precursor forms of the enzyme

Alex de la Fuente, Rocío Rísquez‐Cuadro, Xavier Verdaguer et al. · European Journal of Medicinal Chemistry · 2015 · 24 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +9

Stereoselective synthesis of 2-acetamido-1,2-dideoxynojirimycin (DNJNAc) and ureido-DNJNAc derivatives as new hexosaminidase inhibitors

Alex de la Fuente, Teresa Mena‐Barragán, Ronald A. Farrar‐Tobar et al. · Organic & Biomolecular Chemistry · 2015 · 18 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +5

Phase portraits of the two-body problem with Manev potential

Jaume Llibre, Antonio E. Teruel, Clàudìa Valls et al. · Journal of Physics A Mathematical and General · 2001 · 16 citations

Natural Sciences, Physics, Complex Systems +12

Stereoselective Synthesis of 2-Acetamido-1,2-dideoxyallonojirimycin (DAJNAc), a New Potent Hexosaminidase Inhibitor

Alex de la Fuente, Rubén Martı́n, Teresa Mena‐Barragán et al. · Organic Letters · 2013 · 16 citations

Pharmacy, Medicinal Chemistry, Pharmacology +17

1–5 of 5